Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.08 million versus the consensus estimate of $17.21 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• MIND Technology (MIND) Misses Q1 EPS by 5c
• PreveCeutical closes second tranche of private placement for $245,000